These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the use case for the menopause treatment expected to launch as early as this ...

Registered Dietitian and Nutritionist Kelly Bristow from Bayer shares five simple tips to help families start the year strong ...

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

(Bloomberg) -- Bayer AG plans to push pause on some of ... said in an interview on Monday on the sidelines of the JPMorgan Healthcare Conference in San Francisco. That marks a reversal of comments ...